WITTEN / ACCESSWIRE / March 06, 2019 / The European Patent Office has granted a patent for Sangui's proposed technology/treatment (SBT 102) for septic shock patients, effective March, 6, 2019*. The patent follows up on animal studies carried out by the ECCPS (Excellence Cluster Cardio-Pulmonary System**), Giessen, Germany.
The studies conducted by the ECCPS have resulted in proof-of concept data, utilizing a related technology to Sangui's unique hemoglobin oxygen carrier technology which is already successfully employed by Granulox, a medical device for treatment of chronic wounds. Granulox is distributed by Sastomed GmbH, a fully owned subsidiary of Mölnlycke Health Care GmbH.
The co-authors of the ECCPS studies, Prof. Dr. Ralph Schermuly and Prof. Dr. Ardeshir Ghofrani, come to the conclusion: "We conclude that the intraperitoneal application of SBT 102 is an innovative and effective therapy to avoid tissue hypoxemia. The restoration of intestinal oxygenation will have impact on tissue integrity and finally patient survival."
* Subject to Opposition Period of 9 Months (Article 99 EPC).
** The ECCPS (www.eccps.de) is a joint centre of the Justus-Liebig-University Giessen, the Goethe University Frankfurt and the Max-Planck-Institute for Heart and Lung Research in Bad Nauheim in the field of heart and lung research.
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Sangui Biotech International, Inc.
Thomas Striepe
Fax: +49 (2302) 915191
e-mail: info@sangui.de
Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other "forward-looking" information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: Sangui BioTech International Inc.
View source version on accesswire.com:
https://www.accesswire.com/538177/Sangui-BioTech-International-Inc-Patent-granted-to-Sangui-for-possible-Septic-Shock-treatment
